Haonan Jin, Jiamin Song, Ronglin Gao, Bingxian Sha, Shengyuan Wang, Peiming Luo, Li Yu, Xianghuai Xu, Xuan Wang
Interstitial lung disease (ILD) is a group of diseases involving diffuse pulmonary parenchymal lesions and alveolar inflammation and interstitial fibrosis. Telomeres are repetitive DNA sequences at the end of chromosomes to maintain structural integrity and telomerase can prevent telomere shortening. Telomerase abnormalities such as related gene mutations lead to decrease in telomerase activity and telomere shortening. It has been proven that telomere shortening and telomerase abnormalities are related to the occurrence and development of ILD. Telomere shortening occurs in different types of ILD patients and is associated with prognosis. Gene therapy targeting telomerase exhibits therapeutic potential. The paper elaborates on the progress of telomere shortening in the diagnosis, differential diagnosis, treatment, and prognosis of ILD in recent years, in order to demonstrate its potential and promises and to be helpful for clinical diagnosis and treatment.
{"title":"Telomere Shortening in Interstitial Lung Disease: Challenges and Promises","authors":"Haonan Jin, Jiamin Song, Ronglin Gao, Bingxian Sha, Shengyuan Wang, Peiming Luo, Li Yu, Xianghuai Xu, Xuan Wang","doi":"10.1111/crj.70103","DOIUrl":"https://doi.org/10.1111/crj.70103","url":null,"abstract":"<p>Interstitial lung disease (ILD) is a group of diseases involving diffuse pulmonary parenchymal lesions and alveolar inflammation and interstitial fibrosis. Telomeres are repetitive DNA sequences at the end of chromosomes to maintain structural integrity and telomerase can prevent telomere shortening. Telomerase abnormalities such as related gene mutations lead to decrease in telomerase activity and telomere shortening. It has been proven that telomere shortening and telomerase abnormalities are related to the occurrence and development of ILD. Telomere shortening occurs in different types of ILD patients and is associated with prognosis. Gene therapy targeting telomerase exhibits therapeutic potential. The paper elaborates on the progress of telomere shortening in the diagnosis, differential diagnosis, treatment, and prognosis of ILD in recent years, in order to demonstrate its potential and promises and to be helpful for clinical diagnosis and treatment.</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Asthma is a chronic airway inflammatory disease that significantly affects patients' quality of life and mental health. This study aims to compare the differences between acupoint embedding auxiliary therapy and traditional auxiliary therapy in asthma control, immune response, sleep quality, and quality of life, as well as evaluate their therapeutic effects on patients with asthma.
Methods
A retrospective analysis of 300 patients with asthma was conducted, divided into acupoint catgut embedding and conventional treatment groups. Key assessments included asthma control (ACQ score), exacerbation frequency, HADS, PSQI, and SF-36 for quality of life. Immune markers (IgE, eosinophil count, IL-4, IL-5, IL-10) were measured. Univariate and multivariate logistic regression analyses and ROC curves were used to identify predictors of asthma control and sleep quality. Stratified analysis evaluated differences by asthma severity.
Results
The acupoint catgut embedding group showed significant improvements in asthma control (p < 0.001), exacerbation frequency (p < 0.05), and anxiety and depression (p = 0.0359) compared to the conventional treatment group. IgE (p = 0.00656), eosinophil count (p = 0.0214), and IL-5 (p = 0.0187) were significantly lower, while IL-10 (p = 0.0226) was higher in the acupoint group. Sleep quality (PSQI score, p = 0.0117) and deep sleep (NREM 3, p < 0.05) improved. Asthma severity (p < 0.001) and treatment method (p < 0.001) were significant predictors of outcomes, with model 2 (AUC = 0.731) outperforming model 1 (AUC = 0.649). Stratified analysis showed acupoint therapy was more effective in intermittent and mild asthma.
Conclusion
As an auxiliary treatment, acupoint embedding therapy has shown a good effect in improving the sleep quality of patients with asthma and controlling asthma symptoms, especially in patients with mild-to-moderate asthma.
{"title":"Study on the Combined Effects and Mechanisms of Acupoint Catgut Embedding in Improving Sleep Quality and Controlling Asthma Symptoms in Patients With Asthma","authors":"Zhihong Shi, Wulanqiqige, Qing Quan, Narentuya Zhao, Yanan Wang, Xiaohong Bai, Xiaoyan Hu","doi":"10.1111/crj.70091","DOIUrl":"https://doi.org/10.1111/crj.70091","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Asthma is a chronic airway inflammatory disease that significantly affects patients' quality of life and mental health. This study aims to compare the differences between acupoint embedding auxiliary therapy and traditional auxiliary therapy in asthma control, immune response, sleep quality, and quality of life, as well as evaluate their therapeutic effects on patients with asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis of 300 patients with asthma was conducted, divided into acupoint catgut embedding and conventional treatment groups. Key assessments included asthma control (ACQ score), exacerbation frequency, HADS, PSQI, and SF-36 for quality of life. Immune markers (IgE, eosinophil count, IL-4, IL-5, IL-10) were measured. Univariate and multivariate logistic regression analyses and ROC curves were used to identify predictors of asthma control and sleep quality. Stratified analysis evaluated differences by asthma severity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The acupoint catgut embedding group showed significant improvements in asthma control (<i>p</i> < 0.001), exacerbation frequency (<i>p</i> < 0.05), and anxiety and depression (<i>p</i> = 0.0359) compared to the conventional treatment group. IgE (<i>p</i> = 0.00656), eosinophil count (<i>p</i> = 0.0214), and IL-5 (<i>p</i> = 0.0187) were significantly lower, while IL-10 (<i>p</i> = 0.0226) was higher in the acupoint group. Sleep quality (PSQI score, <i>p</i> = 0.0117) and deep sleep (NREM 3, <i>p</i> < 0.05) improved. Asthma severity (<i>p</i> < 0.001) and treatment method (<i>p</i> < 0.001) were significant predictors of outcomes, with model 2 (AUC = 0.731) outperforming model 1 (AUC = 0.649). Stratified analysis showed acupoint therapy was more effective in intermittent and mild asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>As an auxiliary treatment, acupoint embedding therapy has shown a good effect in improving the sleep quality of patients with asthma and controlling asthma symptoms, especially in patients with mild-to-moderate asthma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The dramatic increase in antidepressant prescribing over the past decade has sparked debate about the possible contribution of antidepressants to elevated cancer risk. In this study, we investigate whether antidepressant use has a causal relationship with lung cancer risk.
Methods
Genome-wide association study (GWAS) data for antidepressant use were acquired from the FinnGen Biobank, while GWAS data for overall lung cancer and specific histological subtypes were obtained from the UK Biobank (UKBB) and IEU databases. The causal impact was evaluated using inverse variance weighting (IVW), MR-Egger regression, and weighted median (WM) approaches. Multiple sensitivity analyses were conducted to validate the findings. Results are expressed as ORs and 95% CIs.
Results
No causal relationship between antidepressant use and lung cancer risk was observed in the IVW (OR = 1.001, 95% CI = 0.999, p = 0.279), MR-Egger (OR = 1.002, 95% CI = 0.992, p = 0.700), and WM analyses (OR = 1.000, 95% CI: 0.997, p = 0.889). Similar results were found across lung cancer subtypes, including lung adenocarcinoma (LUAD) (OR = 1.197, 95% CI = 0.884–1.619, p = 0.247), lung squamous cell carcinoma (LUSC) (OR = 1.052, 95% CI = 0.822, p = 0.688), and small cell lung carcinoma (SCLC) (OR = 1.874, 95% CI = 0.737, p = 0.187). Sensitivity tests confirmed the robustness of these results.
Conclusions
This analysis indicates antidepressant use is not significantly associated with lung cancer risk.
目的：在过去十年中，抗抑郁药处方的急剧增加引发了关于抗抑郁药可能导致癌症风险升高的争论。在这项研究中，我们调查抗抑郁药的使用是否与肺癌风险有因果关系。方法从FinnGen生物银行获得抗抑郁药使用的全基因组关联研究（GWAS）数据，而从UK生物银行（UKBB）和IEU数据库获得总体肺癌和特定组织学亚型的GWAS数据。因果影响的评估采用反方差加权（IVW）、MR-Egger回归和加权中位数（WM）方法。进行多重敏感性分析以验证研究结果。结果以or和95% ci表示。结果在IVW （OR = 1.001, 95% CI = 0.999, p = 0.279）、MR-Egger （OR = 1.002, 95% CI = 0.992, p = 0.700）和WM分析（OR = 1.000, 95% CI: 0.997, p = 0.889）中均未发现抗抑郁药使用与肺癌风险之间的因果关系。在肺癌亚型中也发现了类似的结果，包括肺腺癌（LUAD） （OR = 1.197, 95% CI = 0.884-1.619, p = 0.247）、肺鳞状细胞癌（LUSC） （OR = 1.052, 95% CI = 0.822, p = 0.688）和小细胞肺癌（SCLC） （OR = 1.874, 95% CI = 0.737, p = 0.187）。敏感性试验证实了这些结果的稳健性。结论：该分析表明抗抑郁药的使用与肺癌风险无显著相关性。
{"title":"Exploring the Causal Relationship Between Antidepressant Use and Lung Cancer Risk: A Mendelian Randomization Analysis","authors":"Chunli Yang, Wenlin Xu","doi":"10.1111/crj.70102","DOIUrl":"https://doi.org/10.1111/crj.70102","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>The dramatic increase in antidepressant prescribing over the past decade has sparked debate about the possible contribution of antidepressants to elevated cancer risk. In this study, we investigate whether antidepressant use has a causal relationship with lung cancer risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Genome-wide association study (GWAS) data for antidepressant use were acquired from the FinnGen Biobank, while GWAS data for overall lung cancer and specific histological subtypes were obtained from the UK Biobank (UKBB) and IEU databases. The causal impact was evaluated using inverse variance weighting (IVW), MR-Egger regression, and weighted median (WM) approaches. Multiple sensitivity analyses were conducted to validate the findings. Results are expressed as ORs and 95% CIs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>No causal relationship between antidepressant use and lung cancer risk was observed in the IVW (OR = 1.001, 95% CI = 0.999, <i>p</i> = 0.279), MR-Egger (OR = 1.002, 95% CI = 0.992, <i>p</i> = 0.700), and WM analyses (OR = 1.000, 95% CI: 0.997, <i>p</i> = 0.889). Similar results were found across lung cancer subtypes, including lung adenocarcinoma (LUAD) (OR = 1.197, 95% CI = 0.884–1.619, <i>p</i> = 0.247), lung squamous cell carcinoma (LUSC) (OR = 1.052, 95% CI = 0.822, <i>p</i> = 0.688), and small cell lung carcinoma (SCLC) (OR = 1.874, 95% CI = 0.737, <i>p</i> = 0.187). Sensitivity tests confirmed the robustness of these results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This analysis indicates antidepressant use is not significantly associated with lung cancer risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70102","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaohong Jiang, Qixiang Sun, Yujia Huang, Yuetian Deng, Chaoqian Li
Nebulized inhalation therapy is an important method in the prevention and treatment of respiratory diseases, and inactivated mycobacterial vaccine nebulized inhalation has received a wide attention recently, but the roles and mechanisms are still not fully understood. A literature search showed there is a strong scientific rationale and evidence that nebulized inhalation of inactivated mycobacterial vaccine is effective in the prevention and treatment of respiratory diseases. Clinically available mycobacterial vaccines include Mycobacterium phlei (M. phlei), BCG, and Mycobacterium vaccae (M. vaccae). Nebulized inhalation of inactivated mycobacterial vaccine, especially M. vaccae, has been used in the prevention and treatment of respiratory diseases, such as asthma, respiratory syncytial virus (RSV), coronavirus disease 2019 (COVID-19), and sepsis. It acts on the respiratory tract directly, thus stimulating the body to produce an immune response, enhance respiratory immunity, and achieve prevention and treatment effects. Nebulized inhalation of inactivated mycobacterial vaccine will be an effective therapy in the prevention and treatment of respiratory diseases.
{"title":"Inactivated Mycobacterial Vaccine Nebulized Inhalation: A Effective Therapy for the Prevention and Treatment of Respiratory Diseases?","authors":"Xiaohong Jiang, Qixiang Sun, Yujia Huang, Yuetian Deng, Chaoqian Li","doi":"10.1111/crj.70101","DOIUrl":"https://doi.org/10.1111/crj.70101","url":null,"abstract":"<p>Nebulized inhalation therapy is an important method in the prevention and treatment of respiratory diseases, and inactivated mycobacterial vaccine nebulized inhalation has received a wide attention recently, but the roles and mechanisms are still not fully understood. A literature search showed there is a strong scientific rationale and evidence that nebulized inhalation of inactivated mycobacterial vaccine is effective in the prevention and treatment of respiratory diseases. Clinically available mycobacterial vaccines include <i>Mycobacterium phlei</i> (<i>M. phlei</i>), BCG, and <i>Mycobacterium vaccae</i> (<i>M. vaccae</i>). Nebulized inhalation of inactivated mycobacterial vaccine, especially <i>M. vaccae</i>, has been used in the prevention and treatment of respiratory diseases, such as asthma, respiratory syncytial virus (RSV), coronavirus disease 2019 (COVID-19), and sepsis. It acts on the respiratory tract directly, thus stimulating the body to produce an immune response, enhance respiratory immunity, and achieve prevention and treatment effects. Nebulized inhalation of inactivated mycobacterial vaccine will be an effective therapy in the prevention and treatment of respiratory diseases.</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144525028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Volume OXygenation (VOX) index has good efficacy in predicting the failure of high-flow nasal cannula therapy. However, its predictive value for treatment failure in patients receiving noninvasive ventilation (NIV) remains uncertain.
Methods
Patients who underwent early NIV treatment were grouped based on their 2-h NIV VOX Youden index. The low-risk group consisted of patients with a VOX value > 20.45 (n = 188), while the high-risk group included those with a VOX value ≤ 20.45 (n = 200). Baseline data and arterial blood gas values were collected at 2, 12, and 24 h after NIV initiation.
Results
Compared to the low-risk group, the high-risk group exhibited higher SOFA scores, respiratory rates, and heart rates, along with a lower oxygenation index (P/F) (all p < 0.05). Following NIV treatment, the low-risk group showed a more significant increase in P/F values at 2 h, 12 h, and 24 h after NIV initiation. The low-risk group showed a lower VT and MV (minute ventilation volume) at 2 h, 12 h, and 24 h of NIV (p < 0.05). Moreover, the low-risk group had a lower intubation rate (7.98% vs. 77%, p < 0.05) and mortality rate (4.79% vs. 17.5%, p < 0.05). At 2 h of NIV, the area under the receiver operating characteristic curve for predicting NIV failure using the VOX index was 0.843 (95% CI 0.805–0.882). Using a VOX value threshold of 20.45 to predict NIV failure, the sensitivity was 69.1%, and the specificity was 94.4%. Furthermore, a VOX value ≤ 20.45 was identified as an independent risk factor for tracheal intubation and death.
Conclusions
VOX index shows promise to serve as an effective evaluation index to predict early NIV efficacy in patients with AHRF; a VOX value > 20.45 after 2 h of NIV treatment can better predict improvements in hypoxia, respiratory drive, and NIV outcomes, guide early tracheal intubation in cases of NIV failure, and have a certain predictive effect on patient outcomes.
{"title":"A Multicenter Retrospective Study Predicting Early Noninvasive Ventilation Failure in Patients With Acute Hypoxic Respiratory Failure","authors":"Xiaoyi Liu, Hui Liu, Lijuan Chen, Xiangde Zheng, Hui Ran, Lili Chen, Rui Zhou, Yufeng Wang","doi":"10.1111/crj.70098","DOIUrl":"https://doi.org/10.1111/crj.70098","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Volume OXygenation (VOX) index has good efficacy in predicting the failure of high-flow nasal cannula therapy. However, its predictive value for treatment failure in patients receiving noninvasive ventilation (NIV) remains uncertain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients who underwent early NIV treatment were grouped based on their 2-h NIV VOX Youden index. The low-risk group consisted of patients with a VOX value > 20.45 (<i>n</i> = 188), while the high-risk group included those with a VOX value ≤ 20.45 (<i>n</i> = 200). Baseline data and arterial blood gas values were collected at 2, 12, and 24 h after NIV initiation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to the low-risk group, the high-risk group exhibited higher SOFA scores, respiratory rates, and heart rates, along with a lower oxygenation index (P/F) (all <i>p</i> < 0.05). Following NIV treatment, the low-risk group showed a more significant increase in P/F values at 2 h, 12 h, and 24 h after NIV initiation. The low-risk group showed a lower VT and MV (minute ventilation volume) at 2 h, 12 h, and 24 h of NIV (<i>p</i> < 0.05). Moreover, the low-risk group had a lower intubation rate (7.98% vs. 77%, <i>p</i> < 0.05) and mortality rate (4.79% vs. 17.5%, <i>p</i> < 0.05). At 2 h of NIV, the area under the receiver operating characteristic curve for predicting NIV failure using the VOX index was 0.843 (95% CI 0.805–0.882). Using a VOX value threshold of 20.45 to predict NIV failure, the sensitivity was 69.1%, and the specificity was 94.4%. Furthermore, a VOX value ≤ 20.45 was identified as an independent risk factor for tracheal intubation and death.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>VOX index shows promise to serve as an effective evaluation index to predict early NIV efficacy in patients with AHRF; a VOX value > 20.45 after 2 h of NIV treatment can better predict improvements in hypoxia, respiratory drive, and NIV outcomes, guide early tracheal intubation in cases of NIV failure, and have a certain predictive effect on patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Considerable evidence suggests a strong link between immune cell traits (ICTs) and asthma development via plasma metabolites (PMs), but the causality between ICTs and asthma is still unclear, mainly due to issues like selection bias. Our research was designed to investigate the causality between ICTs, PMs, and asthma and to provide a clearer explanation of these relationships.
Methods
Utilizing the GWAS database, this study employed a two-step, two-sample Mendelian randomization (MR) approach and the inverse variance weighted (IVW) method to investigate the causality between ICTs and asthma, as well as between PMs and asthma. Lastly, we calculated the mediated proportion of PMs as mediators in the link between ICTs and asthma.
Results
Excluding heterogeneity and pleiotropy, MR analysis identified 13 ICTs (CD14 on CD33br HLA DR+ CD14dim, etc.) and asthma causality, and no reverse causality was observed. In addition, 27 PMs (androsterone sulfate levels, succinate levels, etc.) were also causally associated with asthma. Mediate MR indicated −9.81% (−1.2%, −18.4%) of the effect of CD24 on IgD+ CD38br on asthma is mediated by S-methylcysteine sulfoxide levels, with a mediated effect value (p = 0.006) is 0.003 (0.0004, 0.006); 21.4% (6.2%, −36.6%) of the effect of CD3 on CD28+ CD4+ on asthma is mediated by 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels, with a mediated effect value (p = 0.025) is 0.004 (0.001, 0.007).
Conclusions
We identified two pathways by which ICTs can impact asthma through PMs, which might help in identifying potential targets for personalized treatment approaches.
{"title":"Causal Relationships Between Immune Cell Traits, Plasma Metabolites, and Asthma: A Two-Step, Two-Sample Mendelian Randomization Study","authors":"Zhuozheng Hu, Peihao Xu, Jiajun Wu, Weijun Zhou, Yajie Zhou, Lei Xie, Wenxiong Zhang, Yong Cheng","doi":"10.1111/crj.70097","DOIUrl":"https://doi.org/10.1111/crj.70097","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Considerable evidence suggests a strong link between immune cell traits (ICTs) and asthma development via plasma metabolites (PMs), but the causality between ICTs and asthma is still unclear, mainly due to issues like selection bias. Our research was designed to investigate the causality between ICTs, PMs, and asthma and to provide a clearer explanation of these relationships.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Utilizing the GWAS database, this study employed a two-step, two-sample Mendelian randomization (MR) approach and the inverse variance weighted (IVW) method to investigate the causality between ICTs and asthma, as well as between PMs and asthma. Lastly, we calculated the mediated proportion of PMs as mediators in the link between ICTs and asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Excluding heterogeneity and pleiotropy, MR analysis identified 13 ICTs (CD14 on CD33br HLA DR+ CD14dim, etc.) and asthma causality, and no reverse causality was observed. In addition, 27 PMs (androsterone sulfate levels, succinate levels, etc.) were also causally associated with asthma. Mediate MR indicated −9.81% (−1.2%, −18.4%) of the effect of CD24 on IgD+ CD38br on asthma is mediated by S-methylcysteine sulfoxide levels, with a mediated effect value (<i>p</i> = 0.006) is 0.003 (0.0004, 0.006); 21.4% (6.2%, −36.6%) of the effect of CD3 on CD28+ CD4+ on asthma is mediated by 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels, with a mediated effect value (<i>p</i> = 0.025) is 0.004 (0.001, 0.007).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We identified two pathways by which ICTs can impact asthma through PMs, which might help in identifying potential targets for personalized treatment approaches.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70097","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Min Zhang, Jingjing Zhang, Kelei Zhao, Xiaohan Yuan, Jinghang Zhang, Yanting Liu, Ping Lu
This case report features a patient with an invasive thymoma. The patient presented with an anterior mediastinal mass that invaded the left brachiocephalic trunk vein, resulting in the formation of a carcinoma thrombus in the right atrium, superior vena cava, left brachiocephalic trunk vein, and left internal jugular vein (Masaoka stage IV). No indication for surgery was assessed by surgical consultation. After six cycles of chemotherapy and chest radiotherapy, the tumor size decreased from 72.43 to 24 mm, showing a significant improvement in patient efficacy. After a follow-up of 50 months, the patient remained well, without local recurrence or distal metastasis, and maintained a partial response (PR).
{"title":"Patient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP-Endostar Combination Therapy","authors":"Min Zhang, Jingjing Zhang, Kelei Zhao, Xiaohan Yuan, Jinghang Zhang, Yanting Liu, Ping Lu","doi":"10.1111/crj.70081","DOIUrl":"https://doi.org/10.1111/crj.70081","url":null,"abstract":"<p>This case report features a patient with an invasive thymoma. The patient presented with an anterior mediastinal mass that invaded the left brachiocephalic trunk vein, resulting in the formation of a carcinoma thrombus in the right atrium, superior vena cava, left brachiocephalic trunk vein, and left internal jugular vein (Masaoka stage IV). No indication for surgery was assessed by surgical consultation. After six cycles of chemotherapy and chest radiotherapy, the tumor size decreased from 72.43 to 24 mm, showing a significant improvement in patient efficacy. After a follow-up of 50 months, the patient remained well, without local recurrence or distal metastasis, and maintained a partial response (PR).</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Liu, H. Shi, H. Zheng, W. Kong, X. Cheng, L. Deng, “ Circular RNA NFIX Functions as an Oncogene in Non-Small Cell Lung Cancer by Modulating the miR-214-3p/TRIAP1 Axis,” Clinical Respiratory Journal18, no. 8 (2024). https://doi.org/10.1111/crj.13801.
Figures 4 and 7 are incorrect. Below are the correct figures.
FIGURE 4 | Effect of circRNA NFIX interference in NSCLC by targeting miRNA-214-3p. A549 cells were transfected with control-siRNA, circRNA NFIX-siRNA, circRNA NFIX-siRNA + inhibitor control, or circRNA NFIX-siRNA + miR-214-3p inhibitor for 48 h. (A) Cell proliferation was counted by MTT assay. (B and C) The apoptosis ratio of cancer cells was detected by flow cytometry. (D and E) The level of cleaved-caspase3 was detected by western blot assay, and cleaved-caspase3/caspase3 ratio was calculated. ** indicates p < 0.01 versus control-siRNA, ## indicates p < 0.01 circRNA NFIX-siRNA + inhibitor control. Data are exhibited as average ± SD of triple single experiments.
FIGURE 7 | Overexpression of miRNA-214-3p suppressed cell growth and promoted cell apoptosis via TRIAP1 in NSCLC cells. A549 cells were transfected with mimic control, miRNA-214-3p mimic, miRNA-214-3p mimic + control-plasmid, or miRNA-214-3p mimic + TRIAP1-plasmid for 48 h. (A) Cell proliferation was counted by MTT assay. (B and C) The apoptosis of A549 cells was analyzed by flow cytometry. (D and E) The level of cleaved-caspase3 was detected by western blot assay, and the ratio of cleaved-caspase3/caspase3 was determined. ** indicates p < 0.01 versus mimic control, ## indicates p < 0.01 versus miR-214-3p mimic + control-plasmid. Data are exhibited as average ± SD of triple single experiments.
{"title":"Correction to “Circular RNA NFIX Functions as an Oncogene in Non-Small Cell Lung Cancer by Modulating the miR-214-3p/TRIAP1 Axis”","authors":"","doi":"10.1111/crj.70096","DOIUrl":"https://doi.org/10.1111/crj.70096","url":null,"abstract":"<p>\u0000 <span>G. Liu</span>, <span>H. Shi</span>, <span>H. Zheng</span>, <span>W. Kong</span>, <span>X. Cheng</span>, <span>L. Deng</span>, “ <span>Circular RNA NFIX Functions as an Oncogene in Non-Small Cell Lung Cancer by Modulating the miR-214-3p/TRIAP1 Axis</span>,” <i>Clinical Respiratory Journal</i> <span>18</span>, no. <span>8</span> (<span>2024</span>). https://doi.org/10.1111/crj.13801.\u0000 </p><p>Figures 4 and 7 are incorrect. Below are the correct figures.</p><p>FIGURE 4 | Effect of circRNA NFIX interference in NSCLC by targeting miRNA-214-3p. A549 cells were transfected with control-siRNA, circRNA NFIX-siRNA, circRNA NFIX-siRNA + inhibitor control, or circRNA NFIX-siRNA + miR-214-3p inhibitor for 48 h. (A) Cell proliferation was counted by MTT assay. (B and C) The apoptosis ratio of cancer cells was detected by flow cytometry. (D and E) The level of cleaved-caspase3 was detected by western blot assay, and cleaved-caspase3/caspase3 ratio was calculated. ** indicates <i>p</i> < 0.01 versus control-siRNA, ## indicates <i>p</i> < 0.01 circRNA NFIX-siRNA + inhibitor control. Data are exhibited as average ± SD of triple single experiments.</p><p>FIGURE 7 | Overexpression of miRNA-214-3p suppressed cell growth and promoted cell apoptosis via TRIAP1 in NSCLC cells. A549 cells were transfected with mimic control, miRNA-214-3p mimic, miRNA-214-3p mimic + control-plasmid, or miRNA-214-3p mimic + TRIAP1-plasmid for 48 h. (A) Cell proliferation was counted by MTT assay. (B and C) The apoptosis of A549 cells was analyzed by flow cytometry. (D and E) The level of cleaved-caspase3 was detected by western blot assay, and the ratio of cleaved-caspase3/caspase3 was determined. ** indicates <i>p</i> < 0.01 versus mimic control, ## indicates <i>p</i> < 0.01 versus miR-214-3p mimic + control-plasmid. Data are exhibited as average ± SD of triple single experiments.</p><p>We apologize for these errors.</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70096","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The patients with suspected pulmonary embolism (PE) were usually screened using electrocardiogram (ECG) and blood panel of D-dimer, troponin, and blood gas analysis in the emergency.
Objectives
This study aimed to explore a rapid risk model to predict in-hospital adverse events for normotensive PE patients.
Methods
Patients with acute PE having normal blood pressure on appearance were retrospectively enrolled at China-Japan Friendship Hospital from January 2017 to February 2020. The in-hospital adverse events were defined as death and clinical deterioration during hospitalization. The risk model for in-hospital adverse events was generated by multivariate regression analysis. The discrimination ability of the model was compared with PESI, Bova, and FAST risk score, and evaluated by the receiver operating characteristic curve (ROC), net reclassification improvement (NRI), and integrated discrimination improvement index (IDI).
Results
Of the 213 patients, 35 (16.4%) experienced in-hospital adverse events,y including 15 deaths. The average age was 69 ± 19 years, and 118 (44.6%) were females. Multiple logistic regression analysis showed that independent risk factors associated with in-hospital adverse events were low QRS voltage in ECG (OR: 5.321; 95% CI: 1.608–7.310), positive age-adjusted D-dimer (OR: 2.061; 95% CI: 0.622–6.836), positive troponin (OR: 3.504; 95% CI: 1.744–8.259), and PaO2/FiO2 < 300 (OR: 3.268; 95% CI: 0.978–5.260). The ROC analysis showed that the AUC of the new model (0.847, 95% CI: 0.786–0.901) was better than the PESI score (0.628, 95% CI: 0.509–0.769), the Bova score (0.701, 95% CI: 0.594–0.808), and the FAST score (0.775 95% CI: 0.690–0.859).
Conclusion
ECG abnormalities and biomarkers on admission may provide a rapid and effective approach to identify patients with poor prognoses during hospitalization.
{"title":"ECG Abnormalities and Biomarkers Enable Rapid Risk Stratification in Normotensive Patients With Acute Pulmonary Embolism","authors":"Siqi Jiao, Ying Liu, Haoming He, Qing Li, Zhe Wang, Yinong Chen, Longyang Zhu, Shuwen Zheng, Furong Yang, Zhenguo Zhai, Yihong Sun","doi":"10.1111/crj.70060","DOIUrl":"https://doi.org/10.1111/crj.70060","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The patients with suspected pulmonary embolism (PE) were usually screened using electrocardiogram (ECG) and blood panel of D-dimer, troponin, and blood gas analysis in the emergency.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to explore a rapid risk model to predict in-hospital adverse events for normotensive PE patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with acute PE having normal blood pressure on appearance were retrospectively enrolled at China-Japan Friendship Hospital from January 2017 to February 2020. The in-hospital adverse events were defined as death and clinical deterioration during hospitalization. The risk model for in-hospital adverse events was generated by multivariate regression analysis. The discrimination ability of the model was compared with PESI, Bova, and FAST risk score, and evaluated by the receiver operating characteristic curve (ROC), net reclassification improvement (NRI), and integrated discrimination improvement index (IDI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 213 patients, 35 (16.4%) experienced in-hospital adverse events,y including 15 deaths. The average age was 69 ± 19 years, and 118 (44.6%) were females. Multiple logistic regression analysis showed that independent risk factors associated with in-hospital adverse events were low QRS voltage in ECG (OR: 5.321; 95% CI: 1.608–7.310), positive age-adjusted D-dimer (OR: 2.061; 95% CI: 0.622–6.836), positive troponin (OR: 3.504; 95% CI: 1.744–8.259), and PaO<sub>2</sub>/FiO<sub>2</sub> < 300 (OR: 3.268; 95% CI: 0.978–5.260). The ROC analysis showed that the AUC of the new model (0.847, 95% CI: 0.786–0.901) was better than the PESI score (0.628, 95% CI: 0.509–0.769), the Bova score (0.701, 95% CI: 0.594–0.808), and the FAST score (0.775 95% CI: 0.690–0.859).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ECG abnormalities and biomarkers on admission may provide a rapid and effective approach to identify patients with poor prognoses during hospitalization.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70060","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144323356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker elevated in severely ill patients, but its prognostic value in community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate suPAR's prognostic role for CAP severity compared to other biomarkers and severity scores.
Methods
A total of 204 hospitalised CAP patients were enrolled. C-reactive protein (CRP), procalcitonin (PCT), suPAR, CURB-65 and Pneumonia Severity Index (PSI) scores were measured at admission, and patients were followed for 365 days. The primary outcome was the relationship between suPAR levels and CAP severity based on IDSA/ATS guidelines. Secondary outcomes included time to clinical stability (TTCS), length of stay (LOS) and mortality.
Results
Among 204 patients, 174 (85%) had non-severe and 30 (15%) had severe CAP. SuPAR levels were not associated with severe CAP (OR 1.03, 95% CI 0.88–1.21; AUC 0.53). Unlike the PSI and CURB-65 scores, suPAR did not correlate with TTCS (HR PSI 0.80, HR CURB-65 0.86), though all three markers were correlated to LOS (AUC suPAR 0.61). Only suPAR was significantly associated with 30-day mortality (HR 1.51, AUC 0.68).
Conclusions
The prognostic value of suPAR for CAP severity is low, and it does not provide additional prognostic benefit over the CURB-65 or PSI scores in predicting CAP severity. While it has moderate predictive ability for 30-day mortality, its utility for predicting LOS or TTCS is low.
{"title":"The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community-Acquired Pneumonia (CAP)","authors":"Lisa Hessels, Ruud Duijkers, Marianne Schoorl, Lotte Terpstra, Willemien Thijs, Wim Boersma","doi":"10.1111/crj.70089","DOIUrl":"https://doi.org/10.1111/crj.70089","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker elevated in severely ill patients, but its prognostic value in community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate suPAR's prognostic role for CAP severity compared to other biomarkers and severity scores.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 204 hospitalised CAP patients were enrolled. C-reactive protein (CRP), procalcitonin (PCT), suPAR, CURB-65 and Pneumonia Severity Index (PSI) scores were measured at admission, and patients were followed for 365 days. The primary outcome was the relationship between suPAR levels and CAP severity based on IDSA/ATS guidelines. Secondary outcomes included time to clinical stability (TTCS), length of stay (LOS) and mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 204 patients, 174 (85%) had non-severe and 30 (15%) had severe CAP. SuPAR levels were not associated with severe CAP (OR 1.03, 95% CI 0.88–1.21; AUC 0.53). Unlike the PSI and CURB-65 scores, suPAR did not correlate with TTCS (HR PSI 0.80, HR CURB-65 0.86), though all three markers were correlated to LOS (AUC suPAR 0.61). Only suPAR was significantly associated with 30-day mortality (HR 1.51, AUC 0.68).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The prognostic value of suPAR for CAP severity is low, and it does not provide additional prognostic benefit over the CURB-65 or PSI scores in predicting CAP severity. While it has moderate predictive ability for 30-day mortality, its utility for predicting LOS or TTCS is low.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT01964495</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144300385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号